Want to see IN:GLAXO full AI Analyst Report?
GLAXO Stock Chart & Stats
₹2513.25
₹36.90(1.47%)
At close: 4:00 PM EDT
₹2513.25
₹36.90(1.47%)
Day’s Range― - ―
52-Week Range₹2,088.00 - ₹3,202.80
Previous CloseN/A
Volume67.92K
Average Volume (3M)1.83K
Market Cap
₹447.44B
Enterprise Value₹359.33K
Total Cash (Recent Filing)₹27.56B
Total Debt (Recent Filing)₹332.70M
Price to Earnings (P/E)43.1
Beta0.67
Next Earnings
Aug 03, 2026EPS Estimate
13.9Next Dividend Ex-DateN/A
Dividend Yield2.17%
Share Statistics
EPS (TTM)61.15
Shares Outstanding169,406,040
10 Day Avg. Volume1,472
30 Day Avg. Volume1,831
Financial Highlights & Ratios
PEG Ratio3.20
Price to Book (P/B)17.06
Price to Sales (P/S)10.12
P/FCF Ratio39.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)69.1
Revenue Forecast (FY)₹41.94B
Bulls Say, Bears Say
Bulls Say
High And Improving ProfitabilitySustained high margins in 2026 (net ~27%, EBIT ~33%) indicate durable pricing power, efficient cost structure, and favorable product mix in a branded formulation business. This bolsters long-term cash generation, reinvestment capacity, and resilience to sector cyclicality.
Very Conservative Balance Sheet And High ROEExtremely low leverage combined with mid-30s to mid-40s ROE shows efficient use of equity and substantial financial flexibility. Minimal debt reduces refinancing risk and supports strategic optionality (R&D, M&A, buybacks) over the medium term without materially raising solvency risk.
Strong Free Cash Flow ConversionFree cash flow almost matches net income and increased materially in 2025–2026, signaling high earnings quality and reliable internally generated funding. Consistent FCF supports dividends, capex, and strategic investments without heavy external financing.
Bears Say
Profitability Volatility Across YearsWide margin swings (eg, >50% in 2022 vs ~27% in 2026) suggest episodic one-offs or volatile product mix. Such variability complicates medium-term forecasting, capital allocation, and investor visibility, increasing execution and planning risk over the next several quarters.
Operating Cash-flow Conversion VariabilityOCF conversion fluctuates materially due to working-capital timing, meaning cash generation can be lumpy despite high FCF overall. This raises short-to-medium-term liquidity planning risk and can constrain discretionary spending or responsive investment when timing is adverse.
Balance-sheet Volatility In 2022–2023A sharp decline in equity and assets in 2022–2023, even though later rebuilt, indicates prior stress or significant adjustments. The episode highlights potential operational or accounting risks and warrants monitoring for residual exposures or recurrence that could affect medium-term stability.
GlaxoSmithKline Pharmaceuticals Limited News
GLAXO FAQ
What was GlaxoSmithKline Pharmaceuticals Limited’s price range in the past 12 months?
GlaxoSmithKline Pharmaceuticals Limited lowest stock price was ₹2088.00 and its highest was ₹3202.80 in the past 12 months.
What is GlaxoSmithKline Pharmaceuticals Limited’s market cap?
GlaxoSmithKline Pharmaceuticals Limited’s market cap is ₹447.44B.
When is GlaxoSmithKline Pharmaceuticals Limited’s upcoming earnings report date?
GlaxoSmithKline Pharmaceuticals Limited’s upcoming earnings report date is Aug 03, 2026 which is in 3 days.
How were GlaxoSmithKline Pharmaceuticals Limited’s earnings last quarter?
GlaxoSmithKline Pharmaceuticals Limited released its earnings results on May 13, 2026. The company reported ₹16.4 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is GlaxoSmithKline Pharmaceuticals Limited overvalued?
According to Wall Street analysts GlaxoSmithKline Pharmaceuticals Limited’s price is currently Overvalued.
Does GlaxoSmithKline Pharmaceuticals Limited pay dividends?
GlaxoSmithKline Pharmaceuticals Limited pays a Annually dividend of ₹57 which represents an annual dividend yield of 2.17%. See more information on GlaxoSmithKline Pharmaceuticals Limited dividends here
What is GlaxoSmithKline Pharmaceuticals Limited’s EPS estimate?
GlaxoSmithKline Pharmaceuticals Limited’s EPS estimate is 13.9.
How many shares outstanding does GlaxoSmithKline Pharmaceuticals Limited have?
GlaxoSmithKline Pharmaceuticals Limited has 169,406,040 shares outstanding.
What happened to GlaxoSmithKline Pharmaceuticals Limited’s price movement after its last earnings report?
GlaxoSmithKline Pharmaceuticals Limited reported an EPS of ₹16.4 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.685%.
Which hedge fund is a major shareholder of GlaxoSmithKline Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:GLAXO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Technical Analysis
Abbott India Limited
―
Cipla Ltd
―
Gland Pharma Ltd.
―
PFIZER LIMITED
―
Sanofi Consumer Healthcare India Limited
―